Handelsbanken Fonder AB Acquires Shares of 39,000 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Handelsbanken Fonder AB acquired a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 39,000 shares of the company’s stock, valued at approximately $309,000.

Other large investors have also recently bought and sold shares of the company. Gladius Capital Management LP bought a new position in shares of Amneal Pharmaceuticals during the third quarter worth $37,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at about $81,000. Quest Partners LLC bought a new stake in shares of Amneal Pharmaceuticals in the third quarter valued at about $84,000. Janney Montgomery Scott LLC bought a new position in shares of Amneal Pharmaceuticals during the 4th quarter worth approximately $121,000. Finally, Quadrature Capital Ltd bought a new stake in Amneal Pharmaceuticals during the 3rd quarter worth about $169,000. Institutional investors own 31.82% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on AMRX. Piper Sandler upped their price target on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Barclays lifted their price objective on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday. StockNews.com lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, December 19th. Finally, JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $9.00 to $12.00 in a research note on Monday, February 24th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Amneal Pharmaceuticals has a consensus rating of “Buy” and an average price target of $10.80.

Amneal Pharmaceuticals Trading Up 1.0 %

Shares of AMRX opened at $8.76 on Tuesday. The firm’s 50 day moving average is $8.12 and its 200-day moving average is $8.33. The stock has a market capitalization of $2.71 billion, a PE ratio of -12.88 and a beta of 1.10. Amneal Pharmaceuticals, Inc. has a 12 month low of $5.18 and a 12 month high of $9.48.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings results on Friday, February 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.03). The company had revenue of $730.52 million during the quarter, compared to analyst estimates of $708.21 million. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. During the same period last year, the firm earned $0.14 EPS. Equities research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Insider Activity

In other Amneal Pharmaceuticals news, Director Gautam Patel sold 62,590 shares of the business’s stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $8.01, for a total transaction of $501,345.90. Following the completion of the transaction, the director now owns 1,968,886 shares of the company’s stock, valued at approximately $15,770,776.86. The trade was a 3.08 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders sold 160,000 shares of company stock worth $1,292,000. 26.56% of the stock is currently owned by corporate insiders.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.